Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 201

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 201
---
-related securities in the future at a desirable time and price.

Because the purchase price per share to be paid by the Selling Shareholder for the common shares that we may elect to sell to the Selling Shareholder under the SEPA, if any, will fluctuate based on the market prices of our common shares during the applicable pricing period, as of the date of this prospectus we cannot reliably predict the number of common shares that we will sell to the Selling Shareholder under the SEPA, the actual purchase price per share to be paid by the Selling Shareholder for those shares, or the actual gross proceeds to be raised by us from those sales, if any. As of February 10, 2025, there were 11,816,721 our common shares outstanding. If all of the 3,710,000 common shares offered for resale by the Selling Shareholder under the registration statement that includes this prospectus were issued and outstanding as of such date (without taking into account the 4.99% Ownership Limitation or the 19.99% Exchange Cap limitation), such shares would represent approximately 31.4% of the total number of our common shares outstanding as of February 10, 2025.

Although the SEPA provides that we may, in our discretion, from time to time after the date of the SEPA and during the term of the SEPA, direct the Selling Shareholder to purchase common shares from us in one or more Advances under the SEPA, for a maximum aggregate purchase price of up to $15,000,000, only 3,710,000 common shares (105,840 of which represent the Commitment Shares we issued to the Selling Shareholder pursuant to the SEPA as payment for the Selling Shareholder's commitment to purchase common shares under the SEPA) are being registered for resale under the registration statement that includes this prospectus. Assuming all of such 3,710,000 common shares were sold to the Selling Shareholder at the maximum 97.0% discount to the per share price of $2.75 (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding February 10, 2025; or (ii) the average Nasdaq Official Closing Price for the five Trading Days immediately preceding February 10, 2025), such number of shares would be insufficient to enable us to receive aggregate gross proceeds from the sale of such shares to the Selling Shareholder equal to the Selling Shareholder's